---
title: "Rapport Therapeutics CEO Abraham Ceesay sells 2,210 shares worth $92,999.37"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294252845.md"
description: "Rapport Therapeutics CEO Abraham Ceesay sold 2,210 common shares on July 27, 2026, at prices between $42.11 and $42.74, totaling approximately $92,999. Following the transaction, his direct holdings decreased to 537,607 shares. The filing also disclosed additional shares held by the Ceesay Family Irrevocable Trust and the Dorothy Ceesay Irrevocable Trust."
datetime: "2026-07-29T20:05:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294252845.md)
  - [en](https://longbridge.com/en/news/294252845.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294252845.md)
generator: "portal-rs"
---

# Rapport Therapeutics CEO Abraham Ceesay sells 2,210 shares worth $92,999.37

-   Rapport Therapeutics CEO Abraham Ceesay sold 2,210 common shares on July 27, 2026. \* Sales priced at USD 42.11 and USD 42.74. \* Direct holdings fell to 537,607 shares following the transactions. \* Form also reported 81,729 shares held by the Ceesay Family Irrevocable Trust, 20,729 shares held by the Dorothy Ceesay Irrevocable Trust. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-323637), on July 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [RAPP.US](https://longbridge.com/en/quote/RAPP.US.md)

## Related News & Research

- [Rapport Therapeutics to Join Cantor Global Healthcare Conference Fireside Chat](https://longbridge.com/en/news/297773944.md)
- [Rapport Therapeutics Chief Development Officer Krishnaswamy Yeleswaram disposes of common shares worth $2.51 million](https://longbridge.com/en/news/297082004.md)
- [Rapport Therapeutics CEO Abraham Ceesay sells 51,499 shares worth $2.41 million](https://longbridge.com/en/news/295706967.md)
- [Maze Therapeutics CSBO Atul Dandekar disposes of common shares worth $206,823.75](https://longbridge.com/en/news/297567588.md)
- [Palvella Therapeutics director Christopher P. Kiritsy disposes of 313 common shares for $49,141](https://longbridge.com/en/news/298071393.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**